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Abstract
The analysis of adverse events (AEs) is a key component in the assessment of
a drug’s safety profile. Inappropriate analysis methods may result in misleading
conclusions about a therapy’s safety and consequently its benefit-risk ratio. The
statistical analysis of AEs is complicated by the fact that the follow-up times can
vary between the patients included in a clinical trial. This paper takes as its focus
the analysis of AE data in the presence of varying follow-up times within the benefit
assessment of therapeutic interventions. Instead of approaching this issue directly
and solely from an analysis point of view, we first discuss what should be estimated
in the context of safety data, leading to the concept of estimands. Although the
current discussion on estimands is mainly related to efficacy evaluation, the concept
is applicable to safety endpoints as well. Within the framework of estimands, we
present statistical methods for analysing AEs with the focus being on the time
to the occurrence of the first AE of a specific type. We give recommendations
which estimators should be used for the estimands described. Furthermore, we state
practical implications of the analysis of AEs in clinical trials and give an overview of
examples across different indications. We also provide a review of current practices
of health technology assessment (HTA) agencies with respect to the evaluation of
safety data. Finally, we describe problems with meta-analyses of AE data and sketch
possible solutions.
Key words: Adverse events, benefit assessment, estimands, clinical trials, safety data.
11 Setting the scene
The analysis of adverse events (AEs) is a key component in the assessment of a drug’s
safety profile. Inappropriate analysis methods may result in misleading conclusions about
a therapy’s safety and consequently its benefit-risk ratio. A variety of methods are avail-
able for the analysis of AEs, but their complexity and the imposed assumptions clearly
differ. The simplest methods for contingency tables [1], e.g. na¨ıve proportions and derived
effect measures such as risk differences, relative risks and odds ratios, presuppose identi-
cal follow-up times and usually ignore recurrent events and competing risks. If follow-up
times are different across treatment groups, then comparisons based on simple incidence
proportions produce biased results. Consideration of varying follow-up times by means of
incidence densities is possible. However, the incidence density relies on a rather restrictive
constant hazard assumption. Standard procedures for event times [see e.g. 2], in turn,
are based on non-informative censoring and are not readily suitable for recurrent events
and competing risks. For this purpose, more complex methods in the area of event time
analysis do exist [see e.g. 2, Chapters 12–13]; for whose application, however, the data
must in turn meet the corresponding prerequisites.
The purpose of the present paper is to address the research gap in the analysis of AE data
in the spirit of the current discussion on clinical trial estimands. Instead of approaching
the problem of investigating AEs directly and solely from an analysis point of view, we
discuss which quantities should be estimated in the context of safety data, leading to the
concept of safety estimands. Although the current debate on estimands and their role in
clinical trials appears to be mainly related to efficacy evaluation [3, 4], the concept is ap-
plicable to safety endpoints as well. Only very recently this perspective has found its way
into publications such as Akacha et al. [5]. Within the framework of estimands, we present
estimation functions for estimating the quantities of interest, that is, statistical methods
that map the AE data to a single value. In this context, we also describe problems related
to meta-analyses of AE data and sketch possible solutions. Finally, we provide a review
of current practices of health technology assessment (HTA) agencies with respect to the
evaluation of safety data.
2An AE is any unfavourable and unintended sign including an abnormal laboratory find-
ing, symptom, or disease temporarily associated with the exposure to an investigational
product, whether or not considered related to the product [6]. The term “treatment
emergent” is often added to an AE as a modifier in order to remove manifestations of
preexisting conditions from consideration [7]. Adverse events are documented by the in-
vestigator and coded with the Medical Dictionary for Regulatory Activities (MedDRA),
which provides clinically validated medical terminology (https://www.meddra.org/). The
MedDRA includes symptoms, diseases, diagnoses, investigation names and qualitative re-
sults, medical and surgical procedures, social and family history. Adverse events are coded
with the “lowest level terms”. These are combined for the analyses to so-called “preferred
terms”. The latest MedDRA version 21.0 contains more than 22000 preferred terms. As
the present paper focuses on methods for analyzing AEs, we do not report further on
definitions related to AEs or standards for the collection and documentation of AE data.
The remainder of the paper is organized as follows. To begin with, our work is motivated
in Section 2 by giving a brief overview of examples with respect to the analysis of AE data
in clinical trials in different indications. We also provide a review of current practices of
HTA agencies with respect to the evaluation of AE data. The estimand framework is es-
tablished in Section 3. We discuss what should be estimated in the context of safety data
both from a regulatory context and from an HTA perspective. In Section 4, we provide
statistical methods for analysing AEs with the focus being on the time to the occurrence
of first AEs. We also describe some problems and their solutions for meta-analyses of
AE data. In Section 5, we state some recommendations which estimators fit best to the
described estimands. A discussion in Section 6 concludes the paper.
2 Current practice of regulatory and HTA agencies
2.1 Examples
Based on the experience with early benefit assessments by the Institute for Quality and
Efficiency in Health Care (IQWiG) in Germany we looked over some examples whether
variable follow-up times for AEs between individual patients, treatment groups and studies
3are common across different indications.
In general, trials with a primary time-to-event endpoint usually have variable follow-up
times for each individual patient. However, depending on the indication the average
follow-up time between treatment groups can be very different, see Table 1.
*** Insert Table 1 about here ***
In oncology, study treatment is often given until disease progression only with limited
follow-up time for AEs after discontinuation of trial treatment due to subsequent therapies,
resulting in differential follow-up times for the different treatment arms and censored
observations for the occurrence of AEs. Due to the dependency of follow-up time of AEs
on progression-free survival, the treatment group with longer progression-free survival
has a higher likelihood of observing an AE. In such situations, a simple comparison of
incidence proportions between arms is biased in favour of the inferior treatment. In time-
to-event trials with average follow-up times not considerably different between treatment
groups, there can still be variable follow-up times for individual patients. Examples
are large trials in cardiovascular disease, metabolism (diabetes) or respiratory disease
(COPD) with cardiovascular outcomes or mortality as primary endpoint, where mortality
is relatively low.
Other trial designs than time-to-event trials with variable follow-up times were identified
in infectious diseases and central nervous system disorders. For example, there are several
trials with planned trial length in Hepatitis C that allowed shortening the treatment
time either for all patients in the experimental arm or for those in the experimental
arm who achieved an early response. Therefore, the follow-up time in the arm with the
experimental drug was shorter than in the control group, see Table 1. Here, the follow-up
times not only differ between the treatment groups but also between studies of a drug in
the same indication (e.g. Hepatitis C). Comparison of AEs between treatment groups can
be undertaken via incidence proportions only for the duration of the shorter treatment.
It is not possible to demonstrate a potential advantage in terms of lower AE probabilities
over a longer period of time. On the other hand, safety evaluations using na¨ıvely all AEs
on treatment are biased in favour of the treatment group with shorter treatment duration.
For instance, in multiple sclerosis, trials with fixed treatment duration have frequently
4been used, but if control patients switch to treatment in an extension study this would
lead to longer follow-up in the experimental group and AE probabilities that are biased in
favour of the control group. Figure 1 illustrates different scenarios of typical AE follow-up
periods in clinical trials.
*** Insert Figure 1 about here ***
Adverse events are assessed on a regular basis at the visit at the beginning of the trial (V0)
and during treatment (V1,...,Vn). The end of treatment (EoT) triggers a safety follow-up
visit (Saf-FU) marking the last regular safety assessment. Adverse events occurring on
treatment or during safety follow-up are analyzed as treatment-emergent AEs (TEAEs,
marked by bold symbols). First occurrences of AEs (marked by triangles) are in general
considered only when occurring during the TEAE period. Serious AEs may be reported
spontaneously after the safety follow-up visit.
2.2 Regulatory context
Drug approval usually requires a confirmatory proof of efficacy in at least two well con-
ducted randomized controlled trials followed by a benefit-risk assessment that shows that
the treatment’s benefit outweighs the expected risk associated with the new treatment.
In contrast to the demonstration of efficacy as compared to a control, the benefit risk as-
sessment is far less standardized with respect to properly balancing benefit and expected
side effects. Nevertheless, details on clinical trial specifications with respect to the investi-
gated population, the study duration and the number of patients to be studied are given
in several regulatory guidelines, as in therapeutic EMA guidelines (the CHMP clinical
efficacy and safety guidelines), ICH guidelines [8, 9, 10, 11] and U.S. FDA guidelines [12].
Safety assessments in drug approval are usually done with respect to the number and
proportion of patients with specific AEs that occurred in the individual clinical trials,
primarily focusing on the estimated probability of experiencing a given event within the
predefined study duration potentially stratified in relevant subpopulations. It is based on
a limited database available at the marketing authorization application where uncertain-
ties about important risks may either prevent from authorization or imply the requirement
5of post-authorization safety investigations. Due to a number of different side effects, and
since the absence of evidence of an increased risk is not necessarily evidence of absence
of an increased risk [13], the analysis of AEs is often crude and merely descriptive aiming
to detect safety signals, although proposals have been made in the literature on the use
of more sophisticated methods [14, 15, 16]. Study duration may be too short or different
studies may have different durations leading to different rates. In addition the database
from phase III studies may be insufficient to detect infrequent but serious events. In case
of uncertainty the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) may
require that a post-authorisation safety study (PASS) be carried out after a medicine
has been approved. Nevertheless, difficulties in the assessment at the time of marketing
authorization are highly relevant especially in indications with a small patient population
and a high unmet medical need imposing high pressure to the regulatory system.
Hence, an assessment of safety often targets the probability of an AE within a subject and
a given period of time. The safety of a new treatment is assessed using all data available
for this treatment. The FDA, e.g., asks for a document called integrated summary of
safety (ISS) as described in U.S. Food and Drug Administration (FDA) [17]. In contrast
to efficacy assessments, comparative safety assessments are difficult and the appraisal of
side effects is usually done in absolute terms. Even if relative (comparative) safety as-
sessments are given and relate to individual studies, accounting for different observational
times due to study discontinuation, other events and the presence of changing individual
proneness over time is difficult. Competing risks for a number of targeted adverse effects
add another layer of complexity. For example, in two trials involving patients with type 2
diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin
had a lower risk of cardiovascular events than those who received placebo but a greater
risk of amputation of toes, feet, or legs with canagliflozin than with placebo (6.3 vs. 3.4
participants with amputation per 1000 patient-years, corresponding to a hazard ratio
(HR) of 1.97; 95% confidence interval: [1.41, 2.75]) [18]. In such a situation, the increased
risk of amputation might be difficult to determine because of the much larger risk of
mortality in comparison.
62.3 HTAs
2.3.1 The international perspective
The evaluation of safety is considered as an important element of health technology as-
sessments (HTA) [19]. However, due to different approaches to HTA in different health
care systems and little methodological guidance given generally [20], the integration of
safety data and with it the analyses and interpretation of safety data differs considerably.
Some health care systems, such as the one in England, focus on the economic value of a
new technology by implementing a cost effectiveness threshold. Those are usually based
on an incremental cost effectiveness ratio (ICER) or quality-adjusted life years (QALY)
by comparing against the standard of care [21].
In this context data on AEs which are considered most relevant from the patients’ QoL
and/or costing perspective are usually integrated by means of utility functions [22]. A
comprehensive review of the current practice of economic models concludes that there
appears to be an implicit assumption within modelling guidance that adverse effects are
very important. There appears to be a lack of clarity how they should be dealt with and
considered for modelling purposes [23].
Other health care systems, such as the one in Germany, base their decision on the in-
cremental medical benefit against the standard of care [24]. Usually data from clinical
trials are used in order to evaluate the added benefit for all patient relevant endpoints
separately to demonstrate an overall added benefit of the drug for the population in scope.
Typically, a comprehensive description of AEs is provided in those assessments. However,
no specific guidelines with respect to safety analyses are in place in countries following
this approach. In the following, we discuss one specific example.
2.3.2 The current practice at IQWiG in Germany
At the beginning of 2011 the early benefit assessment of new drugs was introduced in
Germany with the Act on the Reform of the Market for Medicinal Products (AMNOG).
The Federal Joint Committee (G-BA) generally commissions the Institute for Quality and
Efficiency in Health Care (IQWiG) with this type of assessment, which examines whether
7a new therapy shows an added benefit (a positive patient-relevant treatment effect) over
the current standard therapy. The IQWiG is required to assess the extent of added ben-
efit on the basis of a dossier submitted by the pharmaceutical company responsible. In
this assessment, the qualitative and quantitative certainty of results within the evidence
presented, as well as the size of observed effects and their consistency, are appraised.
The general methods of IQWiG are described in the Allgemeine Methoden [24, Version
5.0]. In accordance with § 35b (1) Sentence 4 Sozialgesetzbuch (SGB) V, the following
outcomes related to patient benefit are to be given appropriate consideration: increase in
life expectancy, improvement in health status and quality of life, as well as reduction in
disease duration and adverse effects. In the benefit assessment, all patient-relevant end-
points play a role, and for safety, particular consideration is given to serious and severe
AEs as well as treatment discontinuations. In addition, AEs that are of special interest
within the context of the disease or drug class considered may play a role.
For the assessment of the extent of added benefit the effect sizes are of main interest. An
effect size in this context is defined as the (relative) difference between the new treatment
and the appropriate comparator therapy. It is an important step to grade the qualitative
certainty of the estimated effect size e.g. based on trial design, data quality and esti-
mation method. Patients not included into the analyses and patients with incomplete
data increase the risk of bias. Therefore, the following information is gathered and con-
sidered to assess the risk of bias: study design (randomized, open-label or double-blind),
proportion of patients without consideration in the analyses per study arm, proportion
of patients with incomplete data per study arm (censored data, lost-to-follow-up, ...),
reasons for censoring (informative, non-informative, competing risks), distribution of cen-
soring times. Generally, this information is used to assess the direction (in favour of arm
x) and the strength (low or high) of the risk of bias.
In case of varying follow-up times, methods based on survival time analyses are preferred
compared to analyses based on four-fold contingency tables [15]. To classify the risk of
bias the number of the censored patients and the reasons for censoring have to be con-
sidered. Different types of censoring are possible: “uninformatively censored”, “patients
with competing risks” and “informatively censored”, which influence the risk of bias. We
8will elaborate further on this issue in Subsection 4.3.
3 Estimands
3.1 Framework
It is paramount to agree upon the relevant target of estimation defined by the question
what would happen to a specific patient or what is the patient’s risk with respect to a
specific event or multiple events when treated with a given drug as compared to another
drug or to not being treated at all. In the context of efficacy assessments, this concept has
recently been introduced within the framework of estimands in the new draft addendum
R1 to the ICH E9 guideline on statistical principles in clinical trials entitled Estimands
and Sensitivity Analyses in Clinical Trials ; this addendum is referring to the precise pa-
rameter or function of parameters to be estimated in situations where intercurrent events
as treatment discontinuation, death, rescue medication or switch to the other study treat-
ment may influence subsequent measurements [25, 7]. We would like to stress the fact
that the above-mentioned addendum is not yet finalized, hence our expositions in the
sequel can only reflect the current state of discussion. Parts of the draft addendum are
seen critically by HTA agencies [26], and the addendum does not prescribe the use of a
particular estimand in a certain situation. Moreover, the discussion of the application of
the estimands approach to safety data and questions related to benefit-risk assessments
is ongoing and only started recently.
Four different elements are required to describe the estimand of interest: the targeted
population, the endpoint (variable), the intervention effect that describes how intercur-
rent events that potentially influences the endpoint are accounted for, and the summary
measure that summarize the comparison of the two treatments under investigation.
Whereas the nomenclature of types of estimands has been developed and changed dur-
ing the last few years, currently, the following classes of estimands are discussed in the
regulatory context:
9• Treatment policy: treatment policy estimand do not account for any intercurrent
event. The treatment effect is measured irrespective of any intercurrent event, as
treatment discontinuation or additional medication given.
• Composite: composite estimands combine the variable of interest with the in-
tercurrent event, e.g., by defining a treatment failure by the lack of response or
treatment discontinuation.
• Hypothetical: hypothetical estimands target an effect that would occur in the
overall population in a hypothetical scenario, in which no patient experienced the
intercurrent event. E.g., the effect of all patients adhering to treatment constitutes
a hypothetical effect when some patients in fact do not adhere to treatment.
• Prinicpal stratum: principal strata estimands are defined by the subset of patients
in whom the intercurrent event occurs either under one of the treatments or under
both. Since a group comparison trial cannot directly identify these patients with
respect to the not-administered treatment, causal inference methods using specific
assumptions would be required for the analysis.
• While on treatment: while on treatment estimands relate to the effect prior to
the occurrence of an intercurrent event, e.g. before intake of rescue medication or
the effect while being alive.
Although the current discussion is related to the efficacy evaluation, the concept is ap-
plicable to safety endpoints, usually the occurrence of a specific side effect, as well. Con-
sidering the variable of interest as the time to a specific side effect, summary measures
might be given after a specific period of time. Relevant intercurrent events are treatment
discontinuation or switch, death or other side effects that may prevent from the event of
interest.
Whereas the basic idea of an estimand is not restricted to the efficacy assessment, differ-
ent issues related to the large number of event types and the desired “equivalence proof”
combined with the cautionary principle point to somewhat different difficulties. Envis-
aging the chances of a beneficial treatment in the sense of both, efficacy and safety, for
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a given patient may be seen as a concept of incorporating efficacy and safety in an es-
timand, but may be still difficult to be interpreted in the comparison of two treatments
with different safety and efficacy patterns. In that sense, it appears sensible to go along
the lines that are conceived for the efficacy assessment and clarify the precise parameters
in the event analysis in the presence of other concurring events either in relation to the
given treatment, the patient’s condition or competing side effects.
3.2 Estimands in the regulatory context and in HTAs - what to
aim for?
The estimand framework is not specific to the clinical development of new drugs in the
regulatory context but is also relevant to address needs of HTA bodies. The aim of the
HTA process is the assessment of evidence as a basis for further decisions about reim-
bursement, pricing and market access.
Estimands are supposed to focus and describe the research question in detail. As the aims
of drug approval agencies and HTA bodies differ to some extent, different estimands may
be of primary interest, but some overlap in secondary considerations can be expected. The
following considerations focussing on HTA may also apply to the benefit risk assessment
in drug approval. In the German early benefit assessment according to AMNOG, i.e.
§ 35a SGB V, there is a need for the HTA authorities to identify the estimands, which are
not necessarily the same as in the regulatory context to obtain marketing authorization.
For marketing authorization the current practice, in general, is to report estimates for
what could be considered while on treatment estimands to provide evidence for the safety
profile of the treatment of interest. Specific information, however, on AEs occurring in a
long-term follow-up regardless of study drug adherence may be requested in special cases,
which may, however, be hampered by the limited observational period. Potentially dilut-
ing effects of treatment policy estimands in case of treatment discontinuation or switch
may, depending on the treatment comparison and the disease, be anti-conservative for
comparative safety assessments, hence favouring while on treatment estimands for regula-
tory purposes. Certainly, within the context of recent regulatory discussion on estimands
in efficacy, a new regulatory framework also on estimands in safety is needed.
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HTA bodies are most interested in the treatment policy estimand, independently of oc-
currences like rescue therapy (e.g. rheumatoid arthritis) or subsequent therapies (e.g.
oncology). However, in indications like oncology, the AEs are frequently only collected
up to a certain point after last dose of study medication. These data do not support a
treatment policy estimand. In such situations, the evidence for risk assessment is less
strong. It may be difficult or impossible to cover the treatment policy estimand with
the data usually obtained. To obtain sufficient data for a treatment policy estimand and
provide a solid basis for an early benefit assessment, the current practice of how data are
collected in clinical studies needs to be changed [15].
A major challenge in oncology is the treatment change after progression of the dis-
ease, where in many cases patients enter a subsequent clinical study, e.g. in malignant
melanoma where about four years ago the only treatment option was dacarbacin and most
patients entered clinical trials after progression. These studies were under evaluation by
the HTA bodies recently due to the time gap between study conduct and marketing au-
thorization. However, in most studies a patient is not allowed to enter a new clinical
study, if they are still participants of the prior study. As a consequence, they need to
withdraw consent for the first study to enter the next. Therefore, AEs cannot be collected
after progression for the first study in general. Exceptions from this practice are observed
[27], following a protocol recording new onset of serious adverse events up to 90 days after
last dose of study treatment and those serious AEs considered related any time after dis-
continuation of treatment. Another example consists of the German Society of Pediatric
Oncology and Hematology (GPOH) [28], which records further follow-up data on children
after end of treatment and with this provides the possibility for long-term surveillance
and follow-up and late effect evaluation in paediatric oncology patients. Apart from these
examples, the while on treatment estimand is used in clinical trials to avoid bias due
to unbalanced withdrawals in the treatment groups. E.g., if the control treatment is a
standard first line treatment and a subsequent study in second line requires the standard
treatment as first line, then only patients of the control group are allowed to enter the
second line study leading to unbalanced subsequent therapy along with biases in efficacy
but also safety.
12
Four different scenarios, which are displayed in Figure 2, can be distinguished to describe
safety estimands in an HTA system.
*** Insert Figure 2 about here ***
The scenarios in Figure 2 differ according to the lengths of the planned and observed
follow-up times in the study. The definition of estimands becomes increasingly complex
with more pronounced differences in follow-up time due to intercurrent events. In the first
two scenarios, the planned follow-up times of AEs in the study population are similar,
e.g. in trials with fixed trial lengths (see Subsection 2.1). Whereas in Scenario 1, there
are no or only minor differences in observed follow-up times between individual patients
within treatment groups or between treatment groups, in Scenario 2 medium to large
differences in observed follow-up times do exist, due to e.g. high level of treatment or
study discontinuations. Scenarios 3 and 4 consider studies with expected differences in
follow-up times by treatment group, e.g. in oncology (see Subsection 2.1), where AE
reporting stops a certain number of days after last dose of study drug and the time on
study drug differs between treatment groups. In all four scenarios, HTA bodies usually
aim for the treatment policy estimand. However, studies are commonly planned to collect
data that are appropriate for the while on treatment estimand, which is usually the focus
of regulatory agencies in the marketing authorization process. When benefit dossiers are
based on the same studies, it is often not possible to provide estimates of the treatment
policy estimand desired by the HTA agencies due to lack of adequate data. Hence, it is
apparent that the described requirements by HTA bodies with regard to safety analyses
need to be taken into account already in the planning phase of a clinical study.
4 Statistical methodologies
The aim of this Section is to discuss methods for analysing AEs. We focus on the oc-
currence of the first AE of a specific type because the statistical considerations for the
analysis of the first AE are relevant also for the analysis of recurrent AEs. We found a
great variety of methods in the literature, some of which were not well defined, making
it difficult to identify both estimator and estimand. Main methods which focussed on
13
adverse events occurrence in one group were described in the literature as crude rate, in-
cidence proportion, incidence rate, exposure-adjusted incidence rate, hazard function for
adverse events, Kaplan-Meier and cumulative incidence function considering competing
risks. We first describe methods of estimation within one treatment group in Subsec-
tion 4.1, and subsequently the comparison of AE occurrence between samples in Subsec-
tion 4.2. The time point of AE occurrence or comparison thereof will be made explicit.
A major issue will be that safety data need not be completely observed over the whole
study period for all patients and will possibly be right-censored. This requires the use of
time-to-event methodology [16, 14] taking different follow-up times into account, which is
common in efficacy analyses, but less so for safety. In this context, it is often discussed
which kind of censoring is informative, and the role of censoring will briefly be revisited
in Subsection 4.3. Methods for meta-analyses of AE data are discussed in Subsection 4.4.
4.1 Methods of estimation within one treatment group
One major common method is the so-called “crude rate”, which despite its name is in
fact a proportion and is defined as Pˆ(AE) = a/n, where a is the number of patients
observed to experience at least one AE of a specific type and n is the total number of
study patients, see [14], [16], [29], [30], [31] and references therein. The crude rate is a
correct estimator of the probability to experience at least one AE of the interesting type
in case of complete data and identical follow-up times for all patients. With different
follow-up times in different samples, the crude rate will estimate the AE probability at
different points in time. This difficulty is resolved by considering the incidence proportion
([14] and references therein):
Pˆ(AE in [0, t]) =
∑
u≤t
au
n
, (1)
where au denotes the number of patients observed to experience at least one AE of a
specific type at time u. The expression (1) estimates the probability of experiencing at
least one AE within some time-interval [0, t], but is again only valid for complete data
over the considered time interval. In the presence of censoring, both the crude rate and
the incidence proportion underestimate the AE probability [14]. The reason is that these
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methods in fact estimate the probability of both the AE occurrence and the non-occurrence
of censoring.
Some authors, e.g. Ioannidis et al. [30] and Amit et al. [32], therefore suggest to use one
minus the Kaplan-Meier estimator for estimating P(AE in [0, t]), censoring time to AE by
both the end of follow-up and by competing events that preclude AE occurrence such as
death without a prior AE. However, this method overestimates the AE probability [14, 33].
The reason is that one minus the Kaplan-Meier estimator approximates a cumulative
distribution function, implicitly assuming that eventually 100% of all patients experience
the AE under consideration, possibly after death. Therefore, one minus the Kaplan-Meier
estimator must not be used to estimate P(AE in [0, t]) in the presence of competing events
which prevent the occurrence of the AE under consideration.
It is the Aalen-Johansen estimator [34] that generalizes the Kaplan-Meier estimator to
multiple event types and nonparametrically estimates the so-called cumulative incidence
function P(AE in [0, t]), accounting for both competing events [35, 36] and the usual
censoring due to end of follow-up. The Aalen-Johansen estimator for the probability of
AE occurrence is ([14] and references therein):
Pˆ(T ≤ t,AE) =
∑
u≤t
Pˆ(T > u−) · au
nu
, (2)
where T is the time until occurrence of an AE or of a competing event, Pˆ(T > u−) de-
notes the estimate of the probability of not experiencing an AE or the competing event
just prior to time u and nu is the number of patients at risk of observing an AE or a com-
peting event just prior to u. The interpretation of (2) is that of a sum over the empirical
probabilities of experiencing an AE at the observed event times. Here, for estimation of
P(T > u−) the Kaplan-Meier method is used, because the definition of T encompasses
all competing events.
Time-to-event analyses are based on hazards, because in general follow-up times are
incomplete. In fact, the sum over the quotients on the right hand side in (2) is the
Nelson-Aalen estimator of the cumulative AE hazard
∫ t
0
αAE(u)du. For analysing AEs,
the Nelson-Aalen estimator is key in three ways. Firstly, it enters the computation of the
Aalen-Johansen estimator. Secondly, it is closely linked to the Mean Cumulative Func-
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tion which is based on the Nelson-Aalen estimator and is also used in safety analyses [29].
Thirdly, the Nelson-Aalen estimator is the cumulative nonparametric counterpart of the
commonly used incidence rate (or incidence density) of AEs [14, 30, 31]:
IRAE =
a∑
ti
(3)
where ti is the time at risk for patient i and
∑
ti denotes the population time (person-
years) at risk. The incidence rate (3) is an estimator of the AE hazard αAE(t) under a
constant hazard assumption, αAE(t) = αAE for all times t. The incidence rate is popular,
because its denominator accounts for varying follow-up times. Sometimes, the exposure-
adjusted incidence rate is reported by counting in the denominator only the population
time during exposure to study treatment. However, it is not a probability estimator (and
should better not be reported as a percentage). In fact, it is easily seen that depending on
how time is measured (think of milliseconds or decades), the denominator can be made
arbitrarily large or small, possibly resulting in values larger than one.
In perfect analogy to the Aalen-Johansen estimator, translating incidence rates into proba-
bility statements requires incorporating competing events (CEs), e.g. death without prior
AE. For instance, IRAE and the incidence rate of the competing event, IRCE = c/
∑
ti
(writing c for the number of patients observed to experience the competing event), can
be used to obtain a parametric counterpart of the Aalen-Johansen estimator. If constant
event-specific hazards are assumed, the cumulative incidence function of the event type
AE is explicitly given as
P(T ≤ t,AE) =
∫ t
0
αAE · exp (−(αAE + αCE)s) ds (4)
=
αAE
αAE + αCE
(1− exp(−(αAE + αCE)t)) ,
where αCE denotes the competing event hazard. By plugging in both event-specific inci-
dence rates, the cumulative incidence function can be estimated parametrically under a
constant hazards assumption.
We also note that both the Nelson-Aalen estimator and the incidence rate allow for AEs
to be recurrent. In this situation, the translation into probability statements becomes
more complex because of the more complicated recurrent events structure, but also with
recurrent AEs competing events have to be taken into account.
16
4.2 Comparison of treatment groups
When comparing two treatment groups with respect to AE occurrence, often measures like
risk difference, relative risk or odds ratio of crude rates are suggested [e.g. 32]. However, if
such relative measures are used in the presence of censoring and are based on biased one-
sample estimators as discussed above, the result of such a comparison will be biased too,
but the direction of the bias is uncertain. For instance, a ratio of incidence proportions
calculated from censored data will divide something too small by something too small.
As a parametric analysis, the ratio of incidence rates is an appropriate estimator of the
hazard ratio under a constant hazard assumption. The obvious semi-parametric extension
is to use a Cox proportional hazards model,
αAE(t|Z) = αAE;0(t) exp(β>AEZ) , (5)
where αAE;0(t) is an unspecified baseline AE hazard, βAE is the vector of regression coef-
ficients and Z a vector of baseline covariates including treatment group. In other words,
if in (5) the only covariate is treatment group, Z ∈ {0, 1}, then the ratio of the incidence
rate in group 1 to the incidence rate in group 0 estimates the hazard ratio exp(βAE) under
the assumption of a constant baseline hazard for adverse events, αAE;0(t) ≡ constant. If
this assumption is in doubt, any Cox regression software technically censoring the time
to AE by observed competing events will yield the usual maximum partial likelihood es-
timator of exp(βAE). Technically, censoring by observed competing events is in perfect
analogy to calculation of the incidence rates, but, again in analogy to the incidence rates,
it does not allow for probability statements. In other words, the analysis remains some-
what incomplete without consideration of the hazard of the competing event, e.g., via a
second Cox model,
αCE(t|Z) = αCE;0(t) exp(β>CEZ) ,
which technically censors the time to the competing event by observed AEs, see Beyers-
mann et al. [37] for a practical in-depth discussion. A reasonable method of choice will
be a Cox regression model for the event-specific hazards. The important point is that it
requires as many Cox regression models as there are event-specific hazards present. Al-
though fitting two Cox models is straightforward from a computational perspective, the
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presence of two hazards is not without subtleties.
We want to illustrate this using a toy example, assuming, for ease of presentation, con-
stant hazards. We consider a treatment that modifies the AE hazard by a factor of 0.5
and the competing event hazard by a factor of 0.25. As t→∞, one can see from (4) that
P(AE | group 1) in treatment group 1 becomes
0.5 · αAE0
0.5 · αAE0 + 0.25 · αCE0
, (6)
where αAE0 and αCE0 denote the AE hazard and competing event hazard in group 0,
respectively. The expression (6) is greater than P(AE | group 0), although the AE hazard
has been reduced. The reason is simple. In our toy example, treatment reduces both
hazards, thus, delaying both events. Because the effect is larger on the competing event
than on the AE, there will eventually be more AEs in treatment group 1 than in treatment
group 0, such that the cumulative AE probabilities cross at some point in time. This is
illustrated in Figure 3, showing the cumulative AE probabilities in group 0 and group 1
over time for the situation of constant hazards described above.
*** Insert Figure 3 about here ***
In group 0, both the AE hazard rate and the competing event hazard rate were set to
0.02 events per day, eventually leading to an AE probability of 1/2 in group 0 and of 2/3
in group 1. In group 1, the AE hazard is modified by a factor of 0.5 and the competing
event hazard by a factor of 0.25.
Because multiple hazards are present and an analysis of only one hazard does not suf-
fice for probability statements, so-called ‘direct’ approaches such as the Fine and Gray
model for the so-called subdistribution hazard [38] or, easier to interpret, the proportional
odds cumulative incidence function model [39] have been developed. Most popular is per-
haps the Fine and Gray approach, which interprets one minus the cumulative incidence
function as a survival function and fits a Cox model to the corresponding hazard, the
so-called subdistribution hazard. The approach is useful in that a subdistribution hazard
ratio greater (smaller) than one translates into an increase (decrease) of the cumulative
incidence function but is otherwise difficult to interpret [40], because the subdistribution
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hazard, say λ(t|Z), can be expressed as
λ(t|Z) = P(T > t|Z)
1− P(T ≤ t,AE|Z) · αAE(t|Z),
which results in a complicated mixture of effects on the hazard scale and on probability
scales. Alternatives include group comparisons based on confidence bands of the cumula-
tive incidence functions [e.g. 41] or the proportional odds cumulative incidence function
model [39] mentioned above. The latter is a generalization of the logistic regression model
to binomial probabilities P(T ≤ t,AE|Z) as a function of time t and in the presence of
censoring.
4.3 Censoring: independent or informative?
Our presentation so far has demonstrated that the analysis of AE occurrence in trials
with varying follow-up times has to account for differences in follow-up, in particular in
the form of censoring. Survival methodology should not only be used for efficacy, but
also for safety analyses. However, the safety estimands of interest may still be a matter of
debate (see Section 5). Above, we have demonstrated that the relationship between haz-
ards and probabilities is more subtle when competing events that preclude AE occurrence
are present. But even when this is accounted for, there may be a choice between, say
incidence rates and ‘exposure-adjusted incidence rates’ (which are also incidence rates,
but with a different at-risk period, see Subsection 4.1).
Censoring is a concept that pertains to all these aspects, but it is more subtle than may
seem at first glance. So far, we have argued that more standard statistical techniques not
from the field of survival analysis are inappropriate because the analysis will be about AEs
that are observed rather than about AEs that the patient experiences. The observation
time of AEs is often restricted, e.g. in oncological trials often to progression of disease
+ 30 days. The patient may experience AEs after this period but this is not reported
in the case report form (CRF). Next, we have found that one minus the Kaplan-Meier
estimator censoring the time to AE by competing events overestimates the cumulative AE
probability, but that such a censoring approach yields a valid analysis of the AE hazard.
Whether or not censoring yields a valid analysis, has an impact on the estimand at hand,
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of course.
When survival methods for AE analysis are discussed, authors often warn against in-
formative censoring [e.g. 15], but this discussion on censoring is somewhat complicated
by inconsistent terminology in the literature. Random censoring typically refers to the
situation where time-to-event and time-to-censoring are independent random variables
taking values in [0,∞) [e.g. 42, p. 30]. This is also called independent censoring or non-
informative censoring [e.g. 43] in the literature and it is neither uncommon that these
last two terms are used interchangeably [e.g. 2] nor that they refer to different censoring
mechanisms [e.g. 44]. This bedevils the discussion both on AE analyses and estimands,
because one must first define what is meant by, e.g., the term independent censoring,
because different authors may use the term differently, referring to different censoring
mechanisms.
In our context, one will rarely be willing to assume that the time to a certain AE and
the time to a competing event such as death (or progression) without prior AE are inde-
pendent and present themselves as an example of random censoring. In fact, and more
importantly, it is entirely unclear how to define time-to-AE for a patient who has died as
the value of a random variable in the positive real numbers. Such a value would suggest
that there is an AE after death, which is an awkward concept (to say the least), and we
prefer an agnostic point of view.
Above, we have found that observed occurrence of a competing event can be regarded as
‘independent censoring’ in the sense that technically treating it as a censored observation
allows for a correct analysis of the AE hazard. In other words, the analysis of the AE
hazard does not depend on whether censoring was due to administrative closure of the
study or whether it was due to a competing event. On the other hand, observed occur-
rence of a competing event can be regarded as ‘informative censoring’ in the sense that
technically treating it as a censored observation does not allow for a correct analysis of
the AE probability as in a Kaplan-Meier procedure.
These ideas are made rigorous in the counting process approach to survival analysis
[45, 46, 42], see also Allignol et al. [14] for a non-technical account. In a nutshell, censor-
ing by a competing event is independent censoring in that it preserves the desired form
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of the intensity of the counting process of the event under consideration, but it becomes
independent, yet informative censoring if the target parameter is the cumulative incidence
function.
It is worthwhile to reflect on these concepts in oncology trials, where common endpoints
are progression-free survival and overall survival. It is not uncommon that recording of
AEs is stopped for patients who progress and undergo a second line treatment. Of course,
these patients may still experience AEs, and it is generally assumed that the hazard of
an AE after progression is different as compared to before progression. Progression then
is a competing event for AE without prior progression. And progression is a competing
event for death without prior progression and without prior AE. Hence, censoring by the
progression event will yield a valid analysis of the hazards of the other two competing
events, but any probability statement will need to account for all hazards involved. A
different question, however, is what kind of censoring by progression is with respect to
AE occurrence after progression. In a way, the answer is easy: if censoring by progres-
sion events yields a valid analysis of AE occurrence before progression, but if the AE
hazard after progression changes, progression cannot be independent (and, hence, not
non-informative) censoring with respect to AE occurrence after progression.
The argument can be made rigorously by showing that censoring by progression does not
preserve the desired form of the intensity of the AE counting process, if the latter is not
restricted to AEs before progression, but the bottom line is obvious: if recording of AEs
is stopped for patients with diagnosed progression, inference for post-progression AEs is
impossible.
4.4 Meta-analyses of adverse event data
When data from more than one study are available it is not uncommon to na¨ıvely pool
the data across the studies by e.g. “simply combin[ing] the numerator events and the
denominators for the selected studies” [47]. McEntegart [48] and later Ru¨cker and Schu-
macher [49] as well as Chuang-Stein and Beltangady [50] warned of such na¨ıve pooling
as results might be biased due to Simpson’s paradox. The International Conference on
Harmonization (ICH) E9 states that “any statistical procedures used to combine data
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across trials should be described in detail” and that “attention should be paid [...] to the
proper modelling of the various sources of variation”. The use of meta-analysis techniques
is encouraged [51], since these techniques allow for variation in baseline (control group)
outcomes across the various studies. Random-effects meta-analysis in addition allows
for variation in treatment effects across studies (so-called between-trial heterogeneity).
Therefore, this type of models is appropriate to formally combine several studies in one
analysis. In the context of safety analyses a number of specific problems arise [see e.g.
52], some of which will be considered in the following.
Meta-analysis can be carried out using aggregated data of the individual studies or, if
available, individual patient data (IPD). IPD meta-analyses have some advantages over
aggregate data meta-analyses [53], in particular with time-to-event data considered in
this manuscript. If time-to-event data are considered and the meta-analysis is based on
published data, it is sometimes necessary to reconstruct the data by using appropriate
methods [54, 55].
As explained in Subsection 4.2, effect measures such as the risk difference, relative risk or
odds ratio of crude rates are not appropriate when analyzing AE with varying follow-up
times. Alternatives include the ratio of incidence rates, which would be appropriate for
instance under a constant hazard assumption, the hazard ratio estimated in a Cox pro-
portional hazards model or the subdistribution hazard ratio of the popular Fine & Gray
model. For the purpose of meta-analyses these effect measures would be log-transformed
to estimate a combined effect on the log-scale, e.g. log rate ratio or log hazard ratio.
Technically this is fairly straightforward. However, some challenges arise if for example
the follow-up times vary considerably between the studies. Under assumptions such as
proportional hazards the formal combination of studies with different follow-up times are
justified. In practice, however, such assumptions might be challenged. Whereas with a
single study the hazard ratio estimated by weighted Cox regression might be interpreted
as an average effect over follow-up when the proportional hazards assumption does not
hold true [56], this interpretation in the presence of considerably different follow-up times
across studies in a meta-analysis does not apply in the same way. Furthermore, with these
arguments the variation in follow-up times across studies is likely to yield some level of
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between-trial heterogeneity in treatment effects.
Summarizing AE data from a clinical development programme, typically only a small
number of studies is available. Meta-analysis of (very) few studies has recently attracted
more attention as it is also frequently accounted in settings other than the one consid-
ered here. An overview and discussion of the various methods in the context of ben-
efit assessments is provided by [57]. Specifically, empirical studies demonstrated that
between-trial heterogeneity is likely to be present [58], suggesting the use of random-
effects rather than fixed effect meta-analysis. With few studies, however, the between-
trial heterogeneity is difficult to assess with standard methods for random-effects meta-
analysis based on normal approximation yielding confidence intervals for the combined
effect which are too short and which have coverage probabilities well below the nominal
confidence level. This is due to an underestimation of the between-trial heterogeneity and
a failure to account for the uncertainty in the estimation of the heterogeneity. Bayesian
random-effects meta-analysis with weakly informative prior on the between-trial hetero-
geneity (and an uninformative prior on the treatment effect) has been suggested for meta-
analysis with few studies [59, 60]. This avoids zero estimates of the between-trial het-
erogeneity and accounts for uncertainty in the estimation yielding satisfactory coverage
probabilities and interval lengths [61, 62]. Application of the DIRECT algorithm [63],
which is faster than MCMC sampling and does not require inspection of convergence
diagnostics, means that computations are fairly straightforward. An implementation is
available in form of the R package bayesmeta, which can be downloaded from CRAN
(https://cran.r-project.org/package=bayesmeta).
Neal et al. [18] report an integrated analysis of two large-scale randomized placebo-trials
assessing the efficacy and safety of canagliflozin in patients with type 2 diabetes and el-
evated risk of cardiovascular disease. Patients were followed up for varying lengths of
time as the programme was event driven with a constraint on minimum follow-up. In
a stratified Cox regression, a beneficial effect of canagliflozin versus placebo on the pri-
mary outcome time to death from cardiovascular causes, nonfatal myocardial infarction,
or nonfatal stroke, whatever occurred first, was demonstrated (HR = 0.86; 95% confidence
interval (CI): [0.75, 0.97]). For the purpose of illustration, we consider here the AE “low
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trauma fracture”. Figure 4 is a forest plot of the HR with 95% CI from the two studies
CANVAS and CANVAS-R.
*** Insert Figure 4 about here ***
The Figure also includes a fixed-effect meta-analysis, which is in fact very similar to the
stratified Cox regression reported by Neal et al. [18]. As noted by Neal et al. [18], there
was considerable between-trial heterogeneity. Therefore, the use of a random-effects meta-
analysis is indicated. The forest plot includes results from three random-effects meta-
analyses, modified Knapp-Hartung as a frequentist method suggested for meta-analyses
with few studies [64] and Bayesian random-effects meta-analyses with two choices of the
prior for the heterogeneity parameter τ [62]. As can be seen from Figure 4, the modified
Knapp-Hartung method yields a very wide, non-informative interval whereas the Bayesian
intervals are much shorter. In comparison to the fixed-effect model, the Bayesian intervals
are considerably longer as they account for the pronounced between-trial heterogeneity.
Meta-analyses of AE data are further complicated when the events considered are rare.
Normal approximations of the distributions of effects, e.g. log hazard ratios or log odds
ratios, break down with low event rates. In particular if some studies result in zero events
in both arms. Then measures such as (log-)odds ratios cannot be calculated. Among
the remedies proposed for such problems are continuity corrections [65] and models of
the counts such as binomial distributions. The latter can be fitted using likelihood or
Bayesian methods [59, 66, 67]. Very recently, the use of weakly informative priors for the
treatment effect as well as for the between-trial heterogeneity has been shown to result in
satisfactory properties in meta-analyses with few studies and rare events [68].
5 Estimators for described estimands
In the following, the different statistical methods discussed in the previous Section are put
into the context of the estimand framework described in Subsection 3.1 for the specific
situation of the analysis of AEs. The decision on the estimand is made on the study level.
Although in the following we consider estimands of individual studies, the same principle
applies to meta-analyses of AE data. A disadvantage of aggregate data meta-analyses
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in this context is of course that different estimands might have been used in the studies
whereas in IPD meta-analyses the same or at least similar estimands can be applied to
the studies. As with Section 3, our statements are based on the estimands as described in
the draft addendum R1 to the ICH E9 guideline [25], hence the estimands we are referring
to in this Section may be subject to change.
We focus specifically on trials in oncology with differences in follow-up times driven by
progression, discontinuation of treatment, death or end of follow-up. As progression in
general leads to treatment discontinuation, we consider only the intercurrent events treat-
ment discontinuation and death. For all estimands considered in Subsection 3.1, except the
principal stratum estimand, the population is defined by the inclusion and exclusion crite-
ria of the study and contains the treated patients (first element of estimand description).
With respect to the second element of estimand description, for all estimands, the end-
point is the time to the first AE of a specific type. The estimands differ as a consequence of
the following aspects: the follow-up time over which AEs are included in the analysis and
the way how the intercurrent events treatment discontinuation and death are accounted
for (third element of estimand description), and by the population-level summary for
the endpoint (fourth element of estimand description). Here, by ‘intercurrent events’ we
really mean ‘post-randomization events ’, because death is both post-randomization and
terminal, but not truly intercurrent.
Considering the treatment policy estimand, the interest is in the comparison of treatment
groups with respect to AE occurrence until death or end of follow-up, irrespective of the
intercurrent event discontinuation of treatment. So, it includes all AEs until death or
end of study, and, therefore, requires the collection of AE data after treatment discon-
tinuation. The AE hazards of the treatment groups can be compared by calculating the
hazard ratio in a Cox regression model where for patients without AE the time to AE
is censored by death or by end of follow-up. In the interpretation of the result, it has
to be considered if treatment has an effect on the competing event death without prior
AE, i.e. if the hazard ratio between treatment groups with respect to death without prior
AE is different from one. The hazards of the competing event death without prior AE
have also to be taken into account in the estimation of the AE probabilities within the
25
treatment groups by using the Aalen-Johansen estimator. Treatment groups can also be
compared with respect to the AE probabilities by estimating the difference between AE
probabilities at a specified time point or over the whole study period, by calculating the
subdistribution hazard ratio from a Fine and Gray model [38], or by calculating the odds
ratio from a proportional odds cumulative incidence function model [39]. The decision
between treatment comparison by means of hazard functions or by means of probability
functions defines the fourth element of estimand description mentioned above.
The while on treatment estimand includes the AEs until discontinuation of treatment and
requires the collection of AE data up to this event. Treatment groups can be compared
with the same methods as used for the treatment policy estimand, now treating discon-
tinuation of treatment before AE and death without prior AE as competing events.
The composite estimand would combine the interesting event AE with the intercurrent
events treatment discontinuation and death without prior AE. The endpoint is then time
to AE, treatment discontinuation, or death whatever occurs first. So, AE data after treat-
ment discontinuation are not required. However, this does not hold in general for any
intercurrent event. In this situation, no competing events are present and standard sur-
vival analysis techniques can be applied, i.e. the composite event hazards of the treatment
groups can be compared by calculating the hazard ratio in a Cox regression model, and
the probabilities of the composite event can be estimated by one minus the Kaplan-Meier
estimator, where for patients without the composite event, the time to event is censored
by end of follow-up. However, whether such a composite endpoint is an adequate safety
outcome is a different question. We reiterate that any effect on the composite may be
disentangled and effects on the single components of the composite may be analysed using
the techniques discussed in Section 4.
The hypothetical estimand targets the effect of treatment on AE occurrence in the hy-
pothetical scenario in which the intercurrent event treatment discontinuation would not
occur. This estimand requires the collection of AE data only up to this event, under the
assumption that both the AE hazard and the death hazard remain unchanged in this
hypothetical situation. The estimator used for the while on treatment estimand would
be valid also for the hypothetical estimand, but now handling treatment discontinuation
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as a pure censoring event and not as a competing risk. As the assumption is obviously
both untestable and rather strong, sensitivity analyses are a minimum requirement, when
this estimand is targeted. An even more hypothetical estimand would target the effect of
treatment on AE occurrence, assuming that neither treatment discontinuation nor death
before AE occurs. This estimand is even more hypothetical in the sense that one might
be able to imagine situations where treatment continuation is enforced, but enforcing the
absence of death is much more speculative.
The principal stratum estimand builds on the causal framework of potential primary out-
comes. A potential outcome is defined for each possible treatment assignment, but only
one potential outcome is observed, namely that for the actually assigned treatment. This
framework is now extended to potential intercurrent events and targets a causal treat-
ment comparison within subpopulations defined by potential intercurrent events. In our
example, the potential intercurrent event is treatment discontinuation, while alive, as a
function of time and for each possible treatment assignment. A basic principal stratum
contains all patients with identical values for all potential intercurrent events. For the
example of treatment discontinuation (but ignoring time until discontinuation for ease
of presentation) and two possible treatment assignments, one basic principal stratum
is the set of all patients whose potential intercurrent event statuses are (yes, yes); this
is the set of all patients who discontinue treatment under both treatment assignments.
By construction, measuring the difference between potential outcomes on such a basic
principal stratum yields a causal effect ‘adjusting’ for the intercurrent events. Next, a
principal stratum is a union of basic principal strata. A common example is the set of
patients where the potential intercurrent events are unaffected by treatment — (yes, yes)
and (no, no) in the example above — and the complement are all patients where the
potential intercurrent events differ between treatments ((no, yes), (yes, no)). However, it
is impossible to identify these patients in advance, and a post-hoc analysis, e.g., based
only on those patients who did not stop treatment would be biased, one reason being
time-dependent confounding. For the principal stratum estimand causal inference meth-
ods would be required, extending the statistical methods presented in Section 4. Causal
inference methods have been developed for the analysis of time-to-event data [69, 70],
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including methods for competing events [71], but practical applications may be subtle.
For instance, a key concept in causal reasoning is that of a treatment regimen, determined
at time 0. In our context, one may, at least theoretically, envisage enforcing a treatment
regimen of no discontinuation. However, progression events (which trigger treatment dis-
continuation) are not controllable in terms of a ‘progression regimen’, which is one major
motivation behind the principal stratum framework [72].
6 Discussion
The introduction of estimands provides a framework to structure the discussion about
the analyses of AE in terms of specific demands/needs and appropriateness of different
analyses approaches. We formulated a framework based on safety estimands within which
we proposed statistical methods including methods for evidence synthesis that map the
AE data to a single value. For the described estimands we have given recommendations
which estimators should be used. In particular, we would like to advocate the use of time-
to-event methodology for the analysis of AE data, although such a proposal is known for
a quite a long time [35].
As discussed in Subsection 3.2, estimands of primary interest may differ between drug
approval agencies and the HTA bodies in certain instances. The regulatory agencies
evaluate the safety profile of a new treatment. The assessment is based on all safety data
available for the new treatment which is summarized in the summary of safety. There, the
safety profile of the new treatment is provided in detail showing safety data of all kinds (i.e.
AEs, laboratory data, physical examination, vital signs, etc.) of all available studies with
the new treatment to assess the benefit and risk of this treatment. In addition, the safety is
assessed across the whole lifetime of the new treatment by assessing the required periodic
safety updates. The standard approach is to use descriptive statistics such as absolute and
relative frequencies. Common practice evaluates the safety of the treatment itself using a
while on treatment estimand, which could also be formulated as a hypothetical estimand
under relevant assumptions as stated in Section 5. The HTA bodies on the other hand are
interested in the relative effect on AEs of the new treatment in comparison to a chosen
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comparator in the indication of interest. The estimand of interest is the treatment policy.
In indications such as diabetes mellitus, studies may cover both types of estimands if
treatment times and follow-up are similar in both treatment groups. In indications such
as oncological diseases the follow-up of AEs is stopped at the planned end of the study
treatment plus a certain number of days, which often results in considerable differences in
follow-up times. In such scenarios the treatment policy estimands cannot be covered as
AEs usually are not collected for subsequent therapies. A possible solution would be to
plan studies that enable estimates for both estimands. All efforts should be undertaken
while planning and conducting clinical trials to obtain similar follow-up times. In practice,
however, this might not always be possible. Practical challenges include scenarios with
patients moving on to different studies due to treatment failure. In such cases similar
follow-up times cannot be guaranteed. Even if the regulatory agencies have other tasks
than HTA bodies, the general objective is to establish beneficial treatments for patients.
The common parts should be identified in order to harmonize both perspectives.
Further work, some of it under way, can be done or is required in several areas, some of
which have already been mentioned. Firstly, in the present paper, we restricted ourselves
to methods for analysing the time to occurrence of first AEs. Therefore, the methodologies
proposed in this paper need to be revisited with a view to analysing recurrent AEs,
intermittent AEs and AEs with varying severity. Secondly, our proposed methods for
analysing AEs lack from adequately accounting for the occurrence of multiple, different
AEs. Approaches that account for a number of types of possibly related AEs do exist
[73, 74]. Thirdly, an empirical investigation is underway to investigate in a large number
of randomized controlled trials whether the different analyses of AEs lead to different
decisions when comparing safety between groups. Fourthly, it is an open question what
impact regulators and HTA agencies might have on the development of methods for the
analysis of AE data through e.g. the ICH E9 addendum on estimands and sensitivity
analysis in clinical trials. Finally, we have demonstrated that there is a gap between
what would ideally be seen in benefit assessments from an HTA agency perspective and
current practices of how data are collected in trials with an objective to achieve marketing
authorization. It will not be easy to reconcile these two different views. However, the
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present article stimulated the discussion between different stakeholders.
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Table 1: Some examples from early benefit assessments with considerably different follow-
up times. The ratio of the follow-up times in the fourth column is computed by
dividing the follow-up time of the treatment group with shorter follow-up by the
follow-up time of the group with longer follow-up. The dossier assessments can
be obtained from https://www.iqwig.de.
Dossier evaluation Intervention Control Ratio of follow-up times
Oncology Median follow-up + safety follow-up
A14-48 prostate 16.6 months + 28 days 4.6 months + 28 days 31%
A15-17 lung 336 + 28 days 105 + 28 days 37%
A15-33 melanoma 168 + 90 days 63 + 90 days 59%
A16-04 mantle cell lymphoma 14.4 months + 30 days 3.0 months + 30 days 26%
Hepatitis C Planned follow-up + safety follow-up
A14-44 8 - 12 weeks + 30 days 24, 28 or 48 weeks + 30 days 23% - 57%
A16-48 12 weeks + 30 days 24 weeks + 30 days 57%
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V0
1) Fixed length
no survival FU
Withdrawal
Death
Alive, end of FU
V1 V2 V3 EoT Saf-FU
2) Fixed length
incl. survival FU
On-treatment period
Safety-FU period
FU after TEAE period
TEAEs
No TEAE
V0
3) Treatment till
progression incl.
survival FU
V1 V2 Vn
Death
Death
Alive, end of FU
1st AE
…
Figure 1: Description of different scenarios for typical AE follow-up (FU) in clinical trials
(TEAEs: treatment emergent AEs (marked by bold symbols); EoT: end of
treatment; Saf-FU: safety follow-up; V0: visit at the beginning of the trial;
V1,...,Vn: visits during treatment). First occurrences of AEs are marked by
triangles.
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DifferentSimilar
None / minor 
(Scenario 1)
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differences in 
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Figure 2: Flow chart displaying four different scenarios across indications for the consid-
eration of safety estimands in an HTA system.
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Figure 3: Cumulative AE probabilities for two groups and constant hazards. Although
in group 1 the AE hazard is lower compared to group 0, the cumulative AE
probability in group 1 is eventually greater than in group 0.
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study
CANVAS
CANVAS−R
   Fixed effect
   mKH
   Bayes HN(0.5)
   Bayes HN(1.0)
Hazard ratio
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Figure 4: Illustrating example for meta-analyses. Forest plot of hazard ratios for low
trauma fractures as observed in CANVAS and CANVAS-R with 95% CIs and
four combined hazard ratios from a fixed-effect meta-analysis, modified Knapp-
Hartung (mKH) meta-analysis and Bayesian random-effects meta-analysis with
two half-normal (HN) priors for the heterogeneity parameter τ .
